ModifiedUnitedHealthcarePolicy CS129NE.V

Vagus and External Trigeminal Nerve Stimulation (for Nebraska Only)

Policy governing coverage and medical necessity of implantable vagus nerve stimulators and non‑implantable (transcutaneous/external) vagus and trigeminal nerve stimulation devices for members in Nebraska.

Policy Summary

PayerUnitedHealthcare

PolicyVagus and External Trigeminal Nerve Stimulation (for Nebraska Only)

Policy CodePolicy CS129NE.V

Change TypeDocumentation clarifications and supporting updates

Effective DateDecember 1, 2025

Next Review DateN/A

Key ActionObtain and include complete medical-record documentation demonstrating failed trials, exams, and diagnostic results when requesting prior authorization.

SourceLink

POLICY UPDATE CHANGES

Added language specifying that the patient's medical record must contain documentation that fully supports the medical necessity for requested services, including history, exam, and diagnostic test results.

Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.

Removed reference link to the guidelines titled Medical Records Documentation Used for Reviews.

Updated definition of 'Shared Decision Making'.

Updated related policy link title for Transcranial Magnetic Stimulation for Treating Physical Health Conditions (for Nebraska Only).

State‑specificapplies only to Nebraska

2+ trialsrequired prior AED failures

indication-specificevidence mixed by indication

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

multiple sourcesRCTs and guideline citations

several approvalsFDA device clearances referenced

Coverage Criteria and Medical Necessity

Initial coverage criteria for implantable VNS

Covered when ALL of the following are met (context from cited guidance and studies):

Epilepsy - adjunctive VNS: Patient has drug‑resistant epilepsy (seizures not controlled after trials of multiple antiseizure medications) and VNS is considered when resective surgery is not viable or not desired; shared decision‑making documented.documented trials of multiple antiseizure medications

Supported by Epilepsy Society factsheet and NICE guidance

Depression - implantable VNS as adjunctive therapy: Patient has treatment‑resistant depression with adequate prior treatments attempted (multiple medication trials, possibly ECT) and clinician documents discussion of limited/inconclusive evidence and alternatives; use limited to individuals meeting registry/selection criteria with governance, consent, and audit or research arrangements when feasible.history of ≥4 prior treatments or severe/refractory course per registry examples

Long‑term registry data show potential benefit but RCT evidence limited; NICE recommends use with special arrangements

nVNS coverage for cluster headache

Coverage stance for non‑invasive/transcutaneous VNS (nVNS) in cluster headache:

Episodic cluster headache (eCH): nVNS demonstrated superiority to sham for acute treatment in episodic cluster headache in randomized trials and meta‑analysis; may be considered for acute treatment of eCH.evidence of episodic subtype

ACT1/ACT2 and Silberstein/Goadsby analyses support benefit for eCH

Chronic cluster headache (cCH): nVNS did not show consistent benefit for chronic cluster headache in randomized trials and meta‑analyses; evidence is insufficient to support routine coverage for cCH.chronic subtype

Multiple trials show lack of benefit in cCH

Prophylactic nVNS for chronic CH: Some open‑label and randomized prophylactic studies (e.g., PREVA) showed reduced attack frequency when added to standard of care, but limitations (open‑label design, short duration) warrant cautious interpretation; consider a limited trial (e.g., 4 weeks) to identify responders with documented reduction in attack frequency.

Coverage considerations by indication

Coverage considerations based on available evidence:

Episodic cluster headache (eCH) response: Randomized trial evidence shows nVNS produced higher acute and sustained response rates versus sham in episodic cluster headache cohorts, supporting potential coverage with appropriate documentation and a defined trial period.response at 15-60 minutes after treatment in trials

Silberstein et al. and meta‑analysis report significant benefit for eCH

Migraine — selective benefit: Evidence for nVNS and eTNS in migraine is mixed: some RCTs report acute pain relief and improved responder rates in subgroups (e.g., migraine with aura or adherent participants), but overall ITT results are often not statistically significant due to sham activity, adherence, and sample size limitations.≥50% responder rate improvement noted in some analyses

PREMIUM, Najib and Diener trials show subgroup/adherent benefit and limitations

Other neurologic and nonneurologic indications:

Evidence summaries and guideline positions

Evidence summaries and guideline positions relevant to coverage decisions

eTNS for ADHD: A randomized sham‑controlled trial (McGough 2019) in children 8–12 years showed efficacy for ADHD, but guideline review (AAP) concluded evidence is sparse and does not support recommendation for routine use.

AAP does not recommend eTNS for ADHD; further research needed

eTNS for acute migraine: A randomized sham‑controlled trial (Chou 2019) demonstrated significant pain reduction at 1 hour with e‑TNS (Cefaly) versus sham for acute migraine attacks; well tolerated but sample size limitations noted.

Supports acute use with evidence limitations

TNS for depression: A small randomized sham‑controlled phase II study (Generoso 2019) reported reduction in HDRS‑17 scores after a 10‑day TNS protocol with sustained benefit at 1 month, but limited by small sample size and short follow‑up.

Preliminary evidence requiring larger trials

Not medically necessary / Unproven indications

Implantable VNS — Not Medically Necessary for other conditions: Implantable vagus nerve stimulators are considered unproven and not medically necessary for treating conditions other than refractory epilepsy (examples include Alzheimer disease, anxiety, autism, depression, migraine, cluster headache, heart failure, obesity, OCD, Tourette's, upper limb post‑stroke impairment, and others).

List of examples provided in policy

Transcutaneous/external devices — Not Medically Necessary: Transcutaneous (non‑implantable) vagus nerve stimulation devices and external/transcutaneous trigeminal nerve stimulation devices are considered unproven and not medically necessary for preventing or treating all indications.

Policy states these devices are unproven for all indications

Transcutaneous (non‑implantable) vagus nerve stimulation (tVNS) and external/transcutaneous trigeminal nerve stimulation (TNS/eTNS) devices are considered unproven and not medically necessary for all indications. Implantable vagus nerve stimulation (VNS) is addressed separately and is only medically necessary for specific refractory epilepsy criteria; all other proposed implantable VNS uses are considered unproven or not medically necessary. (See list of non‑covered indications below.)

Implantable VNS, whether proposed for psychiatric, neurodegenerative, pain, or cardiovascular conditions, is not medically necessary for indications beyond drug‑resistant epilepsy because current evidence is insufficient to conclude efficacy. Examples of listed non‑covered indications include Alzheimer disease, autism spectrum disorder, anxiety disorders, chronic pain, heart failure, migraine, cluster headaches, obesity, obsessive‑compulsive disorder, Tourette syndrome, and upper limb impairment post‑stroke. Providers should rely on the specific policy language when requesting coverage for these conditions.

Several investigational indications have limited or inconsistent data and are considered experimental/investigational at this time. These include cardiovascular and metabolic conditions such as atrial fibrillation, heart failure, and impaired glucose tolerance, rhythm disorders such as frequent premature ventricular contractions, and a range of neurologic and psychiatric conditions such as tinnitus, schizophrenia, and various sleep quality outcomes. Small study sizes, heterogeneity of protocols, and weak designs prevent conclusions about safety and effectiveness.

The American Academy of Pediatrics does not recommend eTNS as a standard treatment for ADHD because supporting evidence is sparse. The NICE guidance limits use of supraorbital transcutaneous electrical stimulation for migraine: acute treatment may be used only with special arrangements for clinical governance, consent, and audit or research, and preventive use is recommended only in the context of research due to inadequate evidence. These guideline positions should inform coverage and documentation expectations.

This policy is a UnitedHealthcare standard and may not supersede federal, state, or contractual benefit plan requirements. Before applying this policy to a coverage decision, verify the member's specific benefit terms; in the event of a conflict, the federal, state, or contractual requirements govern. Documentation and prior‑authorization processes required by the applicable benefit plan must be followed.

Use of implantable VNS for non‑epilepsy conditions (for example, Alzheimer disease, depression, migraine and cluster headache, obesity, ADHD, autism spectrum disorder, and other psychiatric or neurologic conditions) is considered not medically necessary in this policy because available studies are limited, often small, and methodologically heterogeneous, leaving insufficient evidence of clinical benefit. Requests for such uses should include supporting high‑quality evidence and will be evaluated against benefit plan terms.

Transcutaneous (non‑implantable) vagus nerve stimulation is considered not medically necessary for indications where the evidence is insufficient to establish safety and effectiveness. The policy specifically states that larger, higher‑quality studies are needed and that current study limitations prevent routine clinical use of these non‑implantable devices.

Noninvasive vagus nerve stimulation (nVNS) and external/transcutaneous trigeminal nerve stimulation (eTNS/TNS) for migraine and other conditions generally lack sufficient high‑quality evidence to support routine coverage. While some trials report subgroup or short‑term benefits, heterogeneity in study design, stimulation parameters, sham activity, and adherence issues limit generalizability; routine coverage without robust supporting documentation is not supported.

A systematic review (Boon et al. 2018) and additional summaries indicate there is insufficient data to support TNS for drug‑resistant epilepsy. Although some small studies report promising results, the limited number of trials, variable methodologies, and short follow‑up mean TNS remains investigational for refractory epilepsy until larger, controlled studies confirm benefit and long‑term safety.

Coding and Billing Codes

Applicable CPT/HCPCS/L Codes (group 1)mixed

61885	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array.
61886	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to 2 or more electrode arrays.
64553	Percutaneous implantation of neurostimulator electrode array; cranial nerve.
64568	Open implantation of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator.
64570	Removal of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator.
A4541	Monthly supplies for use of device coded at E0733.
E0733	Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve.
E0735	Noninvasive vagus nerve stimulator.
E0770	Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified.
E1399	Durable medical equipment, miscellaneous.

1–10 of 12

1/2

Applicable L-codes (group 2)mixed

L8682	Implantable neurostimulator radiofrequency receiver.
L8683	Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
L8686	Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension.
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension.
L8688	Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension.

No explicit codes in this excerptmixed

No codes listed

Implantable VNS device product codesmixed

LYJ	FDA product code referenced for implantable vagus nerve stimulators
MUZ	FDA product code referenced for implantable vagus nerve stimulators
QPY	FDA product code referenced for implantable vagus nerve stimulators

Transcutaneous VNS device product codesmixed

PKR	FDA product code referenced for transcutaneous (non-implantable) VNS devices
QAK	FDA product code referenced for transcutaneous (non-implantable) VNS devices

External TNS device product codesmixed

PCC	FDA product code referenced for external/transcutaneous trigeminal nerve stimulation devices
QGL	FDA product code referenced for external/transcutaneous trigeminal nerve stimulation devices

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required per payer process for implantable neurostimulator procedures, device implantation supplies, and specified HCPCS/CPT/L-codes. Requests for implantable VNS (vagus nerve stimulation) must go through the UnitedHealthcare prior authorization process before scheduling implantation.

Affected codes include, but are not limited to: CPT 61885, 61886, 64553, 64568, 64570; HCPCS A4541, E0733, E0735, E0770, E1399; L-codes L8679, L8680, L8682, L8683, L8685–L8688.

Prior Authorization

Device-Specific Prior Authorization

Prior authorization submissions should identify the specific device model and include FDA marketing clearance/product code(s) when applicable. For implantable VNS devices, include product codes such as LYJ, MUZ, QPY when available; for transcutaneous VNS or trigeminal stimulators include applicable PMN/510(k) product codes.

Document device model, manufacturer, and FDA product code(s) (e.g., LYJ, MUZ, QPY, PKR, QAK, PCC, QGL).
Include manufacturer model number and any external transmitter/receiver identifiers (L8682/L8683 references).

Background and Clinical Context

Vagus nerve stimulation (VNS) delivers electrical impulses to the brain via the vagus nerve and is used primarily for drug‑resistant epilepsy. Implantable systems (traditional open‑loop and responsive/closed‑loop variants) are the established modality for epilepsy meeting the policy's criteria, whereas transcutaneous VNS and external TNS/eTNS are noninvasive approaches under investigation and lack sufficient evidence for broad clinical adoption.

Definitions and Terms

Shared Decision Making — Shared Decision Making is a collaborative process between provider and patient considering evidence, provider experience, and patient val...

DefinitionShared Decision Making is a collaborative process in which a provider/clinician and a patient (including caregivers and family) work together to make healthcare decisions; the decision considers evidence-based information about options, the provider's experience, and the patient’s values, goals, preferences, and circumstances.

ComponentsCompares benefits, harms, and risks of each option and discusses what matters most to the patient.

ParticipantsIncludes the patient (and caregivers/family) and the treating provider/clinician as active partners in decision-making.

ReferenceAHRQ, About Shared Decision Making, 2023 (policy source).

AAN Level C — Level C indicates possibly effective, ineffective, or harmful and requires at least one Class II study or two consistent Class III studies.

Policy Summary

PayerUnitedHealthcare

PolicyVagus and External Trigeminal Nerve Stimulation (for Nebraska Only)

Policy CodePolicy CS129NE.V

Change TypeDocumentation clarifications and supporting updates

Effective DateDecember 1, 2025

Next Review DateN/A

Key ActionObtain and include complete medical-record documentation demonstrating failed trials, exams, and diagnostic results when requesting prior authorization.

SourceLink

On This Page

trial of at least 4 weeks with documented attack frequency reduction

Evidence suggests rapid response within 2 weeks; a 4‑week trial can identify responders

For conditions such as ADHD, depression (implantable or external for routine use), atrial fibrillation, tinnitus, epilepsy using eTNS, and others, current evidence is insufficient to conclude safety and efficacy; larger, higher‑quality trials are needed before routine coverage.

Guideline and systematic review cautions and small heterogeneous studies cited

TNS for drug‑resistant epilepsy: A systematic review (Boon 2018) found insufficient data to support efficacy of TNS for drug‑resistant epilepsy.

Additional data collection warranted

Guideline caution: NICE and other guideline bodies note limited quantity/quality of efficacy evidence for transcutaneous neuromodulation; NICE recommends use with special arrangements for some indications and research‑only contexts for preventive applications.

Guideline‑based restrictions (NICE, AAP, AHS position statements)

Note

Verify Benefit Plan and Provide Supporting Documentation

Verify the member’s benefit plan, any federal/state/contractual coverage mandates, and whether prior authorization is required. Provide complete supporting documentation with the prior authorization request to allow medical necessity review.

Check federal, state, and contractual benefit plan requirements before submitting requests.
Attach complete, legible medical records, test results, and prior treatment documentation to the prior authorization request.

Denial Risk

Denial Triggers

Requests may be denied if clinical criteria or required documentation are not met. Transcutaneous (non‑implantable) VNS and external/transcutaneous trigeminal nerve stimulation may be considered unproven for many indications and can be denied when requested for indications lacking sufficient evidence.

Denial trigger: Failure to document that two or more adequate trials of antiepileptic drugs were tried for epilepsy before implantable VNS.
Denial trigger: Requests for transcutaneous (non‑implantable) VNS or external/transcutaneous trigeminal nerve stimulation for indications deemed unproven by this policy.
Denial trigger: Lack of documentation supporting medical necessity (see documentation requirements).

Documentation Required

Medical Records Supporting Necessity

The patient’s medical record must fully support medical necessity. Documentation should be legible, maintained in the medical record, and made available upon request for review.

Required elements include relevant medical history, physical examination findings, and results of pertinent diagnostic tests or procedures.
Documentation of shared decision-making is recommended when applicable (e.g., epilepsy surgery vs VNS).

Documentation Required

Clinical Indication and Prior Therapy Documentation

Document the clinical indication, previous therapies tried, responses or intolerances, and rationale for VNS or other neuromodulation. For epilepsy, explicitly document drug‑resistant status and suitability or unsuitability for epilepsy surgery.

Clinical indication (e.g., drug‑resistant epilepsy, treatment‑resistant depression, migraine subtype, episodic cluster headache).
Documentation that the individual is not a candidate for epilepsy surgery, has failed surgery, or has refused surgery after shared decision-making discussion.
For other indications, document prior standard treatments tried and reasons for failure or intolerance.

Step Therapy

Medication Trial Requirement

For implantable VNS in epilepsy there must be documentation of two or more adequate trials of antiepileptic drug therapy (single or combination) that failed due to lack of efficacy or intolerable side effects before VNS is considered medically necessary.

Specify medications tried (names, doses, duration, reason for discontinuation) and dates of trials.
Provider should document any prior therapeutic failures or intolerances to antiseizure medications.

Documentation Required

Provider Documentation of Prior Trials

Providers should document prior trials comprehensively: medication names, dosages, duration, outcomes, objective seizure frequency records or depression rating scales where applicable, and any adjunctive treatments attempted.

For epilepsy include seizure logs, EEG/MRI findings, and surgical candidacy evaluation notes.
For depression include validated rating scale scores, history of ECT response/nonresponse, and number/type of prior antidepressant treatments.

Step Therapy

Step Therapy Consideration

Consider neuromodulation (including VNS) after failure or intolerance of established pharmacologic therapies; document reasons why further pharmacologic or surgical options are not appropriate. However, no specific step therapy sequence is mandated in this policy segment.

Step therapy consideration: document that established therapies were tried and either failed or were not tolerated prior to neuromodulation.
No step therapy requirements are specified in this policy segment; clinical judgment and benefit plan rules apply.

AAN Level C definitionLevel C indicates possibly effective, ineffective, or harmful (or possibly useful/predictive or not useful/predictive) for the specified condition and population.

Evidence requirementRequires at least one Class II study or two consistent Class III studies to assign Level C.

ImplicationLevel C denotes uncertainty and typically warrants cautious interpretation and further study before routine adoption.

Transcutaneous (non‑implantable) VNS — Non‑implantable devices that stimulate the vagus nerve through the skin; current evidence is insufficient to support routine clinical use...

DefinitionTranscutaneous (non-implantable) VNS refers to devices that stimulate the vagus nerve through the skin (non-implantable approaches).

Evidence statusThere is insufficient evidence to support routine clinical use due to study limitations; larger studies are needed to establish safety, efficacy, and long-term outcomes.

Coverage stancePolicy considers transcutaneous (non-implantable) VNS unproven and not medically necessary for indications lacking supportive evidence.

nVNS (noninvasive vagus nerve stimulation) — External/transcutaneous stimulation of the cervical or auricular branches of the vagus nerve used for acute or preventive treatment of he...

DefinitionnVNS (noninvasive vagus nerve stimulation) denotes external/transcutaneous stimulation of the cervical or auricular branches of the vagus nerve used for acute or preventive treatment of headaches and other studied indications (e.g., gammaCore device).

Cluster headache evidenceRandomized trials (Silberstein et al.) showed nVNS superior to sham for acute treatment in episodic cluster headache (eCH) but not in chronic cluster headache (cCH); sustained response rates favored nVNS for eCH.

Migraine evidencePREMIUM trial found preventive nVNS not superior to sham in the ITT population; post hoc analyses suggested benefit in adherent participants and some subgroups (e.g., with aura).

eTNS / TNS (external/transcutaneous trigeminal nerve stimulation) — External stimulation applied to the trigeminal nerve (e.g., Cefaly device) for acute and preventive migraine treatment and other investig...

DefinitioneTNS/TNS (external/transcutaneous trigeminal nerve stimulation) refers to external stimulation applied to the trigeminal nerve (for example, the Cefaly device) for acute and preventive migraine treatment and other investigational indications.

Evidence summarySystematic reviews and randomized trials report pain reduction and reduced migraine days versus sham, but overall the quality of evidence is low and long-term benefits and optimal protocols are uncertain.

GuidanceUse is limited by guideline assessments (e.g., NICE and AAP) that recommend restricted or research-only use for some indications due to sparse or low-quality evidence.

Device marketing clearance codes — FDA product/marketing codes referenced in the document used to identify cleared implantable and non-implantable VNS and TNS devices (e.g....

Implantable VNS product codesLYJ, MUZ, QPY — FDA product codes referenced for implantable vagus nerve stimulators (see FDA PMA database).

Transcutaneous VNS product codesPKR, QAK — FDA product codes referenced for transcutaneous (non-implantable) VNS devices (see FDA PMN/PMN database).

External TNS product codesPCC, QGL — FDA product codes referenced for external/transcutaneous trigeminal nerve stimulation devices (see FDA PMN database).

Shared Decision Making — Shared Decision Making (updated definition referenced in policy).

Updated definitionShared Decision Making definition updated in policy to emphasize collaborative provider–patient discussion of evidence, provider experience, and patient values/preferences.

Documentation expectationShared Decision Making discussions should be documented in the medical record when relevant to device selection or refusal of alternative treatments.

Policy change notePolicy history indicates the definition of 'Shared Decision Making' was updated (see Policy History/Revision Information).